Dr. John Obourn is Vice President, Androgen Receptor Global Asset Lead at Arvinas. Dr. Obourn has over 20 years of experience and leadership in the strategic pharmaceutical and biotechnology industry from early and late-stage research and drug development through commercialization.
Dr. Obourn joins Arvinas from Alexion Pharmaceuticals, where he served as Global Project Team Leader in Rare Disease and led the company’s first device approval.
Previously, Dr. Obourn was Asset Strategy Lead, Immunology and Neurology at AbbVie. Prior to that, Dr. Obourn spent 16 years at Pfizer in roles of increasing responsibility, including serving as Development Team Head.
Dr. Obourn received his Ph.D. in Toxicology from the University of Rochester and completed his postdoctoral training at DuPont.